Arvinas
$10.61
25
-$0.17-1.58% Tuesday 20:00
Statistics
Day High
11
Day Low
10.28
52W High
13.83
52W Low
6.07
Volume
720,975
Avg. Volume
-
Mkt Cap
681.42M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
30JulExpected
Expected EPS
-0.674522
Actual EPS
N/A
Financials
-75.51%Profit Margin
Unprofitable526.8MRevenue
-397.8MNet Income
Analyst Ratings
17.17Average Price Target
The highest estimate is 24.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy 83%
Hold 17%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow ARVN. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap178B
Gilead Sciences
GILD
Mkt Cap163.4B
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Novartis
NVS
Mkt Cap279.67B
Merck
MRK
Mkt Cap277.02B
Pfizer
PFE
Mkt Cap149.77B
Abbvie
ABBV
Mkt Cap365.43B
Roche
RHHBY
Mkt Cap328.49B
Lilly(Eli) &
LLY
Mkt Cap862.01B
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
About
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Show more...
CEO
Mr. David K. Loomis M.B.A.
Employees
430
Country
United States
ISIN
US04335A1051
Listings
0 Comments
Share your thoughts
FAQ
What is Arvinas stock price today?▼
The current price of ARVN is $10.61 USD — it has decreased by -1.58% in the past 24 hours. Watch Arvinas stock price performance more closely on the chart.
What is Arvinas stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Arvinas stocks are traded under the ticker ARVN.
Is Arvinas stock price growing?▼
ARVN stock has risen by +8.04% compared to the previous week, the month change is a -5.44% fall, over the last year Arvinas has showed a +52.66% increase.
What is Arvinas market cap?▼
Today Arvinas has the market capitalization of 681.42M
When is the next Arvinas earnings date?▼
Arvinas is going to release the next earnings report on May 12, 2026.
What were Arvinas earnings last quarter?▼
ARVN earnings for the last quarter are -1.1 USD per share, whereas the estimation was -0.51 USD resulting in a -114.24% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Arvinas revenue for the last year?▼
Arvinas revenue for the last year amounts to 526.8M USD.
What is Arvinas net income for the last year?▼
ARVN net income for the last year is -397.8M USD.
How many employees does Arvinas have?▼
As of May 06, 2026, the company has 430 employees.
In which sector is Arvinas located?▼
Arvinas operates in the Health & Wellness sector.
When did Arvinas complete a stock split?▼
Arvinas has not had any recent stock splits.
Where is Arvinas headquartered?▼
Arvinas is headquartered in New Haven, United States.